Effects of multiple ascending doses of the glucagon receptor antagonist <scp>PF</scp> ‐06291874 in patients with type 2 diabetes mellitus

Abstract

PF-06291874 was well tolerated, has a pharmacokinetic profile suitable for once-daily dosing, and results in reductions in glucose with minimal risk of hypoglycaemia.